Pfizer, Starboard Value
Despite that cash windfall, Pfizer has "dramatically underperformed its peers and the market since 2019," according to ...
Activist investor Starboard Value is baring its teeth at Pfizer management, more openly going after CEO Albert Bourla’s job.
Activist hedge fund Starboard Value's chief executive officer said on Tuesday that drugmaker Pfizer's board needs to hold ...
Starboard Value criticizes Pfizer's leadership for underperformance, citing a 50% stock decline and missed growth targets ...
1don MSN
Jeff Smith, Starboard Value CEO, joins CNBC's 'Squawk on the Street' to discuss how he sees Pfizer going forward, potential ...
The activist investor claims Pfizer failed to capitalize on the windfall earned from its COVID-19 vaccine and, in the process, destroyed tens of billions of dollars in market value.
Activist hedge fund Starboard Value believes the root cause of Pfizer’s issues are the low expected returns on its research and development investments, including investments done both internally and ...
Activist investor Starboard Value, which picked up a $1 billion stake in Pfizer earlier this month, now reportedly has ...
Starboard Value LP Chief Executive Officer Jeffrey Smith said there has been at least $20 billion in value destruction at drugmaker Pfizer Inc., which he admonished for failing to deliver on a ...
Former Pfizer CEO Ian Read and ex-CFO Frank D'Amelio said they will not be involved with activist investor Starboard Value, ...
Investor's Business Daily on MSN1d
Starboard Hammers Pfizer Execs For Failing To Deliver On 'Best Pipeline' PromisesStarboard took aim at Pfizer in another blow Tuesday, saying the company has failed to deliver on what it called the "best ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback